Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mason Ruiz, Ningyan Zhang, Anil K Sood & Zhiqiang An. (2022) Antibody therapeutics for epithelial ovarian cancer. Expert Opinion on Biological Therapy 22:11, pages 1379-1391.
Read now
Read now
Robert E. Jordan, Xuejun Fan, Georgina Salazar, Ningyan Zhang & Zhiqiang An. (2018) Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy. OncoImmunology 7:9.
Read now
Read now
Joseph M. Ryan, Jeffrey S. Wasser, Adam J. Adler & Anthony T. Vella. (2016) Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy 16:5, pages 655-674.
Read now
Read now
Ningyan Zhang, Robert E. Jordan & Zhiqiang An. (2016) Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function. OncoImmunology 5:5.
Read now
Read now
Articles from other publishers (27)
Nicola Gaynor, Alfonso Blanco, Stephen F. Madden, Barry Moran, Jean M. Fletcher, Damien Kaukonen, Javier Sánchez Ramírez, Alex J. Eustace, Martina S. J. McDermott, Alexandra Canonici, Sinead Toomey, Ausra Teiserskiene, Bryan T. Hennessy, Norma O’Donovan, John Crown & Denis M. Collins. (2023) Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy. British Journal of Cancer 129:6, pages 1022-1031.
Crossref
Crossref
Carly M. Van Wagoner, Fátima Rivera‐Escalera, Nydia C. Jaimes‐Delgadillo, Charles C. Chu, Clive S. Zent & Michael R. Elliott. (2023) Antibody‐mediated phagocytosis in cancer immunotherapy. Immunological Reviews 319:1, pages 128-141.
Crossref
Crossref
V. V. Smirnov, O. A. Petukhova, A. V. Filatov, D. A. Kudlay & M. R. Khaitov. (2023) Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies. Biological Products. Prevention, Diagnosis, Treatment 23:2, pages 173-180.
Crossref
Crossref
Mahshad Entezam, Mohammad-Javad Sanaei, Yousef Mirzaei, Ali Hussein Mer, Meghdad Abdollahpour-Alitappeh, Fatemeh Azadegan-Dehkordi & Nader Bagheri. (2023) Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sciences 318, pages 121459.
Crossref
Crossref
Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia & Jun Zhu. (2022) Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Frontiers in Oncology 12.
Crossref
Crossref
Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Shun Ma, Xinrong He, Dennis Xia, Max Wang, Michelle Xia & Baiyong Li. (2022) Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Frontiers in Immunology 13.
Crossref
Crossref
George DelidakisJin Eyun Kim, Katia George & George Georgiou. (2022) Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations. Annual Review of Biomedical Engineering 24:1, pages 249-274.
Crossref
Crossref
Bingxuan Li, Xiaohong Qin & Li-Zhi Mi. (2022) Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development. Nanoscale 14:19, pages 7110-7122.
Crossref
Crossref
Chensu Wang, Ang Cui, Maurice Bukenya, Aereas Aung, Dikshant Pradhan, Charles A. Whittaker, Yash Agarwal, Ayush Thomas, Simon Liang, Parastoo Amlashi, Heikyung Suh, Stefani Spranger, Nir Hacohen & Darrell J. Irvine. (2021) Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell Reports 37:8, pages 110021.
Crossref
Crossref
Bo Xu, Lei Tian, Jing Chen, Jing Wang, Rui Ma, Wenjuan Dong, Aimin Li, Jianying Zhang, E. Antonio Chiocca, Balveen Kaur, Mingye Feng, Michael A. Caligiuri & Jianhua Yu. (2021) An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nature Communications 12:1.
Crossref
Crossref
Miho Nagayasu & Kazuhisa Ozeki. (2021) Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice. Pharmaceutical Research 38:4, pages 583-592.
Crossref
Crossref
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre & Sheri L. Moores. (2020) Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics 19:10, pages 2044-2056.
Crossref
Crossref
Joshua Yang, Jiahong Sun, Demi M. Castellanos, William M. Pardridge & Rachita K. Sumbria. (2020) Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice. Molecular Pharmaceutics 17:8, pages 2831-2839.
Crossref
Crossref
Tae Hyun Kang & Sang Taek Jung. (2020) Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer. Biomolecules 10:3, pages 382.
Crossref
Crossref
Jaeseung Lim. 2020. Second Generation Cell and Gene-based Therapies. Second Generation Cell and Gene-based Therapies
91
155
.
Vaishali Aggarwal, Katrin Sak, Diwakar Aggarwal, Gaurav Parashar, Nidarshana Chaturvedi Parashar, Shivani Sood, Muobarak Jaber Tuorkey, Jagjit Kaur, Harpal Singh Buttar & Hardeep Singh Tuli. 2020. Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models. Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
213
228
.
Mark L. Chiu, Dennis R. Goulet, Alexey Teplyakov & Gary L. Gilliland. (2019) Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8:4, pages 55.
Crossref
Crossref
Shea Jassem, Wei Wang, Heather Sweet, Raffi Manoukian, Vincent Chow, Palanisamy Kanakaraj, Katariina M. Hutterer, Scott Kuhns, Ian N. Foltz, Qing Chen, John Ferbas & Helen J. McBride. (2019) Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab. Pharmaceutical Research 36:12.
Crossref
Crossref
María Sofía Castelli, Paul McGonigle & Pamela J. Hornby. (2019) The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology Research & Perspectives 7:6.
Crossref
Crossref
Joseph Ryan Polli, Frank A. Engler & Joseph P. Balthasar. (2019) Physiologically Based Modeling of the Pharmacokinetics of “Catch-and-Release” Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models. Journal of Pharmaceutical Sciences 108:1, pages 674-691.
Crossref
Crossref
Tong Zhang, Xiaomin Song, Lanlan Xu, Jie Ma, Yanjuan Zhang, Wenfeng Gong, Yilu Zhang, Xiaosui Zhou, Zuobai Wang, Yali Wang, Yingdi Shi, Huichen Bai, Ning Liu, Xiaolong Yang, Xinxin Cui, Yanping Cao, Qi Liu, Jing Song, Yucheng Li, Zhiyu Tang, Mingming Guo, Lai Wang & Kang Li. (2018) The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunology, Immunotherapy 67:7, pages 1079-1090.
Crossref
Crossref
Lucy E. Métayer, Anna Vilalta, G.A. Amos Burke & Guy C. Brown. (2017)
Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages
via
the Fc domain, resulting in cell death by phagoptosis
. Oncotarget 8:37, pages 60892-60903.
Crossref
Crossref
Peng Gao, Kenneth L. Pinkston, Agathe Bourgogne, Barbara E. Murray, Ambro van Hoof & Barrett R. Harvey. (2017) Functional studies of E. faecalis RNase J2 and its role in virulence and fitness. PLOS ONE 12:4, pages e0175212.
Crossref
Crossref
Abdullah F. U. H. Saeed, Rongzhi Wang, Sumei Ling & Shihua Wang. (2017) Antibody Engineering for Pursuing a Healthier Future. Frontiers in Microbiology 8.
Crossref
Crossref
Paul D. Wes, Faten A. Sayed, Frédérique Bard & Li Gan. (2016) Targeting microglia for the treatment of Alzheimer's Disease. Glia 64:10, pages 1710-1732.
Crossref
Crossref
Randall J Brezski & George Georgiou. (2016) Immunoglobulin isotype knowledge and application to Fc engineering. Current Opinion in Immunology 40, pages 62-69.
Crossref
Crossref
Stephen A. Beers, Martin J. Glennie & Ann L. White. (2016) Influence of immunoglobulin isotype on therapeutic antibody function. Blood 127:9, pages 1097-1101.
Crossref
Crossref